NasdaqGM - Nasdaq Real Time Price USD

CorMedix Inc. (CRMD)

Compare
9.59
-0.77
(-7.43%)
At close: March 3 at 4:00:02 PM EST
9.72
+0.13
+(1.36%)
After hours: 7:43:01 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Joseph Todisco MBA CEO & Director 1.07M -- 1976
Dr. Matthew T. David M.D. Executive VP & CFO 597.27k -- 1977
Ms. Erin Mistry Executive VP & Chief Commercial Officer 561.57k -- 1982
Ms. Elizabeth Masson-Hurlburt B.A. Executive VP and Chief Clinical Strategy & Operations Officer 538.91k -- 1979
Ms. Kaufman Beth Zelnick Esq. EVP, Chief Legal, Compliance Officer & Corporate Secretary -- -- 1961
Donna Ucci Senior VP & Head of Global Quality -- -- --
Dr. Tushar Mukherjee Senior VP & Head of Technical Operations -- -- --

CorMedix Inc.

300 Connell Drive
Suite 4200
Berkeley Heights, NJ 07922
United States
908 517 9500 https://www.cormedix.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
82

Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Corporate Governance

CorMedix Inc.’s ISS Governance QualityScore as of March 1, 2025 is 5. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 1; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 10, 2025 at 12:30 PM UTC - March 14, 2025 at 12:30 PM UTC

CorMedix Inc. Earnings Date

Recent Events

January 7, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 25, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 21, 2024 at 2:00 PM UTC

Annual Shareholders Meeting

November 14, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

October 30, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 8, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

August 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 20, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

May 9, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

March 12, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.